A systematic review found biological therapies for IBD, such as anti-TNF agents and natalizumab, were more effective than a placebo in inducing remission for some patients with active Crohn's disease and ulcerative colitis, according to one analysis published as part of a comprehensive evidence-based review of medical therapies for IBD sponsored by the American College of Gastroenterology and published online March 15. Read the abstract here.

Related Summaries